通过AAV介导的α-synuclein向体内的脑内表达改善了老老鼠的运动功能
Kuo-Jen Wu1, Yu-Sung Chiu2,3, Seong-Jin Yu4
1School of Pharmacy, College of Pharmacy, China Medical University, Taichung, Taiwan.
Scientific reports
|January 7, 2026
概括
使用NAC32体内基因治疗减少了老老鼠的α-synuclein (αSyn) 积累,改善了运动缺陷并保持了多巴胺功能. 这种方法对治疗与衰老相关的帕金森病 (PD) 和其他αSyn障碍有希望.
科学领域:
- 神经科学是一个神经科学.
- 基因治疗 基因治疗
- 神经退行性疾病 神经退行性疾病
背景情况:
- 在多巴胺能神经元中的α-synuclein (αSyn) 积累是帕金森病 (PD) 发病的核心,特别是在老年人中.
- 衰老会加剧αSyn水平和多巴胺基变性,导致运动障碍.
- 之前的研究表明,由腺相关病毒1 (AAV1) 介导的NAC32体内表达减少了αSyn和小鼠中的布拉迪基尼西亚.
研究的目的:
- 调查黑色物质中AAV介导的NAC32体内表达是否可以改善与年龄相关的αSyn相关的多巴胺功能障碍和老老鼠的运动缺陷.
- 阐明NAC32降低αSyn水平的机制.
主要方法:
- 将AAV1-NAC32基因传递到老老鼠的黑质体中.
- 评估行为表现,多巴胺基标记物 (铁酸酶 - TH),突触标记物和αSyn水平.
- 研究αSyn减少机制,包括蛋白质体,溶酶体和自相体路径,以及αSyn mRNA水平.
主要成果:
- 在老老鼠中,NAC32体内表达显著降低了αSyn积累和αSynmRNA水平,而不依赖于主要降解途径.
- 在老老鼠中,治疗恢复了TH表达,增加了突触标记物和条纹性多巴胺,改善了运动运动活动.
- 在大批条纹组织中没有检测到促炎性细胞因子的升高.
结论:
- 黑色物质中AAV介导的NAC32体内表达有效地减轻了老老鼠的αSyn诱导的多巴胺功能障碍和运动障碍.
- 这种基因治疗方法对与年龄相关的帕金森病和其他以αSyn病理学为特征的疾病具有治疗潜力.
更多相关视频
09:16Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
Published on: June 26, 2018
8.0K
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.5K
相关概念视频
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...